Baker Bros. Advisors LP Seagen Inc. Transaction History

Baker Bros. Advisors LP

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Aug 14, 2023	SELL	$187.64 - $206.25 $443 Million - $487 Million	-2,359,607 Reduced 5.03%	44,554,162 $8.57 Billion
Q1 2023 May 15, 2023	BUY	$127.59 - $203.08 $191,767 - $305,229	1,503 Added 0.0%	46,913,769 $9.5 Billion
Q1 2022 May 16, 2022	BUY	$119.61 - $157.85 $2.26 Million - $2.98 Million	18,902 Added 0.04%	46,912,266 $6.76 Billion
Q4 2021 Feb 14, 2022	SELL	$142.57 - $190.86 $56.3 Million - $75.4 Million	-394,895 Reduced 0.84%	46,893,364 $7.25 Billion
Q2 2021 Aug 16, 2021	BUY	$135.08 - $161.1 $2.36 Million - $2.82 Million	17,500 Added 0.04%	47,288,259 $7.47 Billion

Q1 2021 May 17, 2021	BUY	$137.51 - $190.8 $183,575 - $254,718	1,335 Added 0.0%	47,270,759 $6.56 Billion
Q3 2020 Nov 16, 2020	BUY	$145.95 - $195.69 $6.9 Billion - $9.25 Billion	47,269,424 New	47,269,424 $9.25 Billion

1.26M

23K

55.2K

Ticker SGEN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 185,664,992
Description
Seagen Inc., a biotechnology company, develops and commercializes therapies for the treatment of cancer in the United States and internationally. The company offers ADCETRIS, an antibody-drug conjugate (ADC) for the treatment of patients with Hodgkin lymphoma or CD30-positive T-cell lymphomas; PADCEV, an ADC targeting Nectin-4 for the treatment ...

Get notified when there are updates to the investment portfolio of Baker Bros. Advisors LP, based on Form 13F filings with the SEC.

Stay updated on Baker Bros. Advisors LP with notifications on news.